{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:00:58Z","timestamp":1775671258529,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01636-9","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:40:59Z","timestamp":1743712859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Meta-analysis of the comparative efficacy and safety of new drugs in combination with chemotherapy in primary plasmoblastic lymphoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Bingling","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"8","key":"1636_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ajh.27376","volume":"99","author":"A Ramirez-Gamero","year":"2024","unstructured":"Ramirez-Gamero A, Martinez-Cordero H, Beltran BE, et al. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(8):1586\u201394.","journal-title":"Am J Hematol"},{"issue":"3","key":"1636_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","volume":"15","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293\u20139.","journal-title":"Oncologist"},{"issue":"2","key":"1636_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.2023021348","volume":"143","author":"PR Di Ciaccio","year":"2024","unstructured":"Di Ciaccio PR, Polizzotto MN, Cwynarski K, et al. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024;143(2):152\u201365.","journal-title":"Blood"},{"issue":"3","key":"1636_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","volume":"22","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Brown J, Abramson JS, et al. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(3):175\u2013204.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1636_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413\u201320.","journal-title":"Blood"},{"issue":"1","key":"1636_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1601-0825.2008.01493.x","volume":"15","author":"P Rafaniello Raviele","year":"2009","unstructured":"Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15(1):38\u201345.","journal-title":"Oral Dis"},{"issue":"3","key":"1636_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood.V97.3.744","volume":"97","author":"A Carbone","year":"2001","unstructured":"Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1\/IRF4, BCL-6, and CD138\/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3):744\u201351.","journal-title":"Blood"},{"key":"1636_CR8","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"H Stein","year":"2017","unstructured":"Stein H, Harris N, Campo E, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. IARC; 2017.","edition":"4"},{"issue":"4","key":"1636_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00277-016-2601-6","volume":"95","author":"PL Fedele","year":"2016","unstructured":"Fedele PL, Gregory GP, Gilbertson M, et al. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016;95(4):667\u20138.","journal-title":"Ann Hematol"},{"issue":"15","key":"1636_CR10","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323\u201330.","journal-title":"Blood"},{"issue":"10","key":"1636_CR11","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ajh.21250","volume":"83","author":"J Castillo","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804\u20139.","journal-title":"Am J Hematol"},{"issue":"34","key":"1636_CR12","doi-asserted-by":"publisher","first-page":"e704","DOI":"10.1200\/JCO.2010.30.0038","volume":"28","author":"M Bibas","year":"2010","unstructured":"Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010;28(34):e704\u20138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1636_CR13","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1002\/cncr.26723","volume":"118","author":"SK Barta","year":"2012","unstructured":"Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118(16):3977\u201383.","journal-title":"Cancer"},{"issue":"4","key":"1636_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15156","volume":"184","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679\u201382.","journal-title":"Br J Haematol"},{"issue":"9","key":"1636_CR15","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","volume":"59","author":"C Dittus","year":"2018","unstructured":"Dittus C, Grover N, Ellsworth S, et al. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma. 2018;59(9):2121\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1636_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.bbmt.2015.03.008","volume":"21","author":"C Cattaneo","year":"2015","unstructured":"Cattaneo C, Finel H, McQuaker G, et al. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant. 2015;21(6):1146\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1636_CR17","first-page":"456","volume":"41","author":"WJ Fu","year":"2020","unstructured":"Fu WJ, He MX, Huang AJ, et al. Clinical characteristics and survival analysis of 15 cases of HIV-negative plasmablastic lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2020;41(6):456\u201361.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"1636_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jha2.807","volume":"5","author":"N Dong","year":"2024","unstructured":"Dong N, Zhang H, Song J, et al. B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem. 2024;5(1):285\u20139.","journal-title":"EJHaem"},{"issue":"2","key":"1636_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjh.18399","volume":"199","author":"R Jessa","year":"2022","unstructured":"Jessa R, Chien N, Villa D, et al. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Br J Haematol. 2022;199(2):230\u20138.","journal-title":"Br J Haematol"},{"issue":"12","key":"1636_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/QAD.0000000000002590","volume":"34","author":"B Mai","year":"2020","unstructured":"Mai B, Wang W, Lin M, et al. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. AIDS. 2020;34(12):1735\u201343.","journal-title":"AIDS"},{"issue":"6","key":"1636_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12185-016-2082-3","volume":"104","author":"Y Koizumi","year":"2016","unstructured":"Koizumi Y, Uehira T, Ota Y, et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol. 2016;104(6):669\u201381.","journal-title":"Int J Hematol"},{"issue":"8","key":"1636_CR22","first-page":"837","volume":"23","author":"N Rapiti","year":"2022","unstructured":"Rapiti N, Peer N, Abdelatif N, et al. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal. South Africa HIV Med. 2022;23(8):837\u201348.","journal-title":"South Africa HIV Med"},{"issue":"7","key":"1636_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","volume":"57","author":"A Noy","year":"2016","unstructured":"Noy A, Lensing SY, Moore PC, et al. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS malignancy consortium. Leuk Lymphoma. 2016;57(7):1731\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1636_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/sajc.sajc_186_16","volume":"6","author":"AH Rudresha","year":"2017","unstructured":"Rudresha AH, Lakshmaiah KC, Agarwal A, et al. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India. South Asian J Cancer. 2017;6(2):69\u201371.","journal-title":"South Asian J Cancer"},{"key":"1636_CR25","doi-asserted-by":"publisher","first-page":"106391","DOI":"10.1016\/j.leukres.2020.106391","volume":"95","author":"PK Jayachandran","year":"2020","unstructured":"Jayachandran PK, Rajan AK, Karunakaran P, et al. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy. Leuk Res. 2020;95:106391.","journal-title":"Leuk Res"},{"issue":"12","key":"1636_CR26","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","volume":"31","author":"BM Holderness","year":"2013","unstructured":"Holderness BM, Malhotra S, Levy NB, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013;31(12):e197\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1636_CR27","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1636_CR28","first-page":"174","volume":"51","author":"FG Rosado","year":"2021","unstructured":"Rosado FG, Coberly J, Gupta A, et al. PD1\/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation. Ann Clin Lab Sci. 2021;51(2):174\u201381.","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"1636_CR29","doi-asserted-by":"publisher","first-page":"E390","DOI":"10.1002\/ajh.26291","volume":"96","author":"JJ Castillo","year":"2021","unstructured":"Castillo JJ, Lamacchia J, Silver J, et al. Complete response to pembrolizumab and radiation in a patient with HIV-negative EBV-positive plasmablastic lymphoma. Am J Hematol. 2021;96(10):E390\u20132.","journal-title":"Am J Hematol"},{"issue":"5","key":"1636_CR30","doi-asserted-by":"publisher","first-page":"e006684","DOI":"10.1136\/jitc-2023-006684","volume":"11","author":"S Raghunandan","year":"2023","unstructured":"Raghunandan S, Pauly M, Blum WG, et al. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. J Immunother Cancer. 2023;11(5):e006684.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1636_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/ajh.26784","volume":"98","author":"BT Hess","year":"2023","unstructured":"Hess BT, Giri A, Park Y, et al. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023;98(2):300\u20138.","journal-title":"Am J Hematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01636-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:11Z","timestamp":1764917351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01636-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01636-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"103"}}